Illumina, Teladoc Health, and Vertex Pharmaceuticals enjoy strong competitive advantages and great growth opportunities.
News & Analysis: Illumina
These stocks are leading the way in their respective areas in battling cancer.
These companies could make a big difference in how the disease is diagnosed and treated. And their stocks could make a big difference for long-term investors.
These stocks are bargains.
They're leaders in their markets. And those markets should grow tremendously.
These companies focused on genetics, glamor, and gaming are worth considering for the long haul.
The gene sequencing pioneer could face several scenarios in the future -- from very good to very bad.
Find out why this team of Motley Fool contributors believe these businesses are strong buys right now.
ILMN earnings call for the period ending March 31, 2019.
The gene-sequencing leader's revenue and earnings growth rates slowed down in the first quarter, but stronger growth is likely on the way.